Related Blog Posts from the Wikinvest Wire

Novartis AG (NVS)   Subscribe to Novartis AG (NVS) content from the Wikinvest Wire
 » Back to Novartis AG (NYSE:NVS) Stock Page

  

8/21/14Stock Update: Eli Lilly & Company (NYSE:LLY) – Lilly psoriasis drug impresses; battle nears wit... (Jutia Group)

[Reuters] - An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc's blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by Amgen and Novartis AG. Based on favorable results from Phase III trials, Lilly said Thursday it would seek marketing approval in [...]

12/3/13Company Update – Eli Lilly and Company (NYSE:LLY) – Novartis Veterinary Unit Said to Draw Int... (Jutia Group)

[at Bloomberg] - Novartis AG’s animal-health business is drawing interest from drugmakers including Eli Lilly & Co. and Merck & Co. as the Swiss pharmaceutical giant prepares to sell the unit, people with knowledge of ... Read more on this. Eli Lilly and Company (LLY), currently valued at $53.82B, opened this morning at [...]

12/3/13Company Update: Merck & Co. Inc. (NYSE:MRK) – Novartis Veterinary Unit Said to Draw Interest Fr... (Jutia Group)

[at Bloomberg] - Novartis AG’s animal-health business is drawing interest from drugmakers including Eli Lilly & Co. and Merck & Co. as the Swiss pharmaceutical giant prepares to sell the unit, people with knowledge of ... Read more on this. Merck & Co. Inc. (MRK), currently valued at $144.40B, started trading this morning [...]

7/23/13(NVS) Positive Data on Novartis’ Afinitor (Stock Blog Hub)

Novartis (NVS) recently announced positive results on Afinitor, from a phase III trial, BOLERO-3. The study is evaluating Novartis’ Afinitor plus Roche’s (RHHBY) Herceptin and vinorelbine for the treatment of women suffering from HER2 positive (HER2+) advanced breast cancer. It was observed in the trial (n= 569) that Afinitor plus Herceptin and vinorelbine significantly extended progression-free [...]

4/27/13(NVS) Theravance – Glaxo Drug to Face FDA Panel (Stock Blog Hub)

The US Food and Drug Administration (FDA) recently released briefing documents ahead of the review by its Pulmonary-Allergy Drugs Advisory Committee of the New Drug Application (NDA) of Theravance/Glaxo’s (THRX/GSK) candidate FF/VI (furoate/vilanterol, proposed brand name: Breo Ellipta). The FDA panel is scheduled to review the NDA on Apr 17, 2013. The companies are looking to [...]

4/4/13(NVS) Novartis Drug Candidate Earns Good News (Stock Blog Hub)

Novartis (NVS) recently announced that the US Food and Drug Administration (FDA) rendered Breakthrough Therapy designation to its pipeline candidate LDK378. The Breakthrough Therapy designation includes all the features involved in a fast track program in addition to a more intensive FDA guidance. This designation from the FDA expedites the development and review of drugs for [...]

3/22/13Novartis’ TOBI Podhaler Gets FDA Approval (Penny Stock DD)

Novartis AG's (NVS: Quote) TOBI Podhaler has been approved by the FDA for the management of cystic fibrosis patients with Pseudomonas aeruginosa, a bacterium that causes lung infections. Cystic fibrosis, or CF, is an inherited disease characterized by the buildup of thick, sticky mucus, and it affects the lungs and digestive system. About 80% of people [...]

3/21/134 Reasons to Buy this Leading Drug Stock Right Now (Jutia Group)

The Food and Drug Administration's new "breakthrough" status is making big waves in the biotech world. Under the federal agency's "breakthrough" product designation, passed in July of 2012, the most promising drugs have an opportunity to move directly from Phase I testing to commercialization. That's a big time and money saver. Now drug companies have [...]

3/13/13(NVS) Novartis Announces Positive Drug Approval News (Stock Blog Hub)

Novartis (NVS) recently announced that the European Commission (EC) has approved its drug llaris (canakinumab, ACZ885) for an additional indication. The EC cleared llaris for treating adults suffering from gouty arthritis (gout) - a serious, chronic and progressive inflammatory disease. Patients experience attacks of gout when the body has a strong inflammatory response to the uric [...]

1/9/13Biotech Collaborates with Startup on Cancer Drug (Wealth Daily)

Major biotech Amgen (NASDAQ: AMGN) is working with a startup to create a drug targeting cancer cells.

1/2/13(PETS) PetMed Express Stays at Neutral (Stock Blog Hub)

We have reaffirmed our Neutral recommendation on PetMed Express (PETS), following its second-quarter fiscal 2013 results. PetMed reported earnings per share (EPS) of 20 cents in the quarter, a penny ahead of the year-ago quarter and also above the Zacks Consensus Estimate of 17cents per share. Net sales remained almost unchanged at $58.1 million, but surpassed [...]

11/8/12Novartis Promises 14 New Big-Selling Drugs In Five Years (ValueWalk.com)

Officials at drug maker Novartis AG (NYSE:NVS) say they could have at least 14 new major drugs on the market within the next five years. The drug maker is currently focusing on treatments for respiratory problems, heart problems, and cancer. Like most other drug makers, Novartis AG (NYSE:NVS) is also facing competition as some of the [...]

11/1/12Company to Build Singapore Biotech Facility (Wealth Daily)

Novartis (NYSE: NVS) is investing $500 million to develop its presence in Singapore...

10/9/12(NVS) Novartis’ Votubia Earns Positive Comments from Committee for Medicinal Products for Human... (Stock Blog Hub)

Switzerland-based pharmaceutical company, Novartis AG (NVS) recently announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) gave a positive opinion on Votubia (everolimus) for the treatment of patients suffering from renal angiomyolipoma, associated with tuberous sclerosis complex (TSC). On approval, the drug can be used in patients who [...]

7/19/12Novartis Q2 Earnings Trumps Analysts’ Estimates (Value Investing)

Novartis AG (NYSE:NVS) reported earnings for second quarter of 2012.  The Swiss pharmaceutical major reported a $2.73 billion profit, which is almost equal to last year's corresponding quarter's $2.72 billion in income. Novartis reported that second-quarter earnings per share fell 7 percent to 138 cents, which trumps analyst estimates of 133 cents in Reuters poll. The total [...]

7/9/12Novartis: Buy Before The Bullish Rally (Investment Underground » Page not found)

Novartis AG (NVS) recently made a significant breakthrough in the domain of cancer treatment, making it one of the stocks to seriously watch. With some recent news about other breakthroughs, Novartis is poised to not only increase in this quarter, but for quarters to come. The stock is right in the middle of its 52-week [...]

6/24/12Napodano: Zipsor A Nice Fit For Depomed ()

On June 21, 2012, Depomed (DEPO) announced the acquisition of the product Zipsor (diclofenac potassium) Liquid Filled Capsules from privately-held Xanodyne Pharmaceuticals, Inc. Zipsor is a non-steroidal anti-inflammatory drug (NSAID) indicated for relief of mild to moderate acute pain in adults. The product uses the proprietary ProSorb delivery technology (developed by AAIPharma Services Corp) to [...]

5/31/12Novartis Looks Cheap. But... (EPIC INVESTOR)

Pharmaceutical company Novartis (NVS) looks attractive right now from some financial angles. But is Novartis a great company to own going forward? Judging from its history of earnings and dividends, it seems to either lack good management or a defensible business moat. But I'm getting ahead of myself. First, let's look at why it might be cheap. Why NVS might be cheap: Dividend Growth Model For the last 12 years (the most data I have available), NVS increased its dividend an annualized...

12/12/11(NVS) Novartis’ Cancer Drug Afinitor Shows Promise for Breast Cancer (Stock Blog Hub)

Novartis’ (NVS) cancer drug Afinitor took a significant step forward, as the company once again presented encouraging data from late-stage trials of Afinitor for the treatment of breast cancer, an indication for which management estimates sales potential in excess of $1 billion. Afinitor is not yet approved for the treatment of breast cancer. The pivotal late-stage [...]

11/28/11(NVS) Novartis’ Rasitrio Cleared in European Union (Stock Blog Hub)

Novartis (NVS) recently announced that its triple combination hypertension pill Rasitrio has been cleared in the European Union (EU). Rasitrio combines the currently marketed hypertension pill Razilez (marketed as Tekturna in the US) with amlodipine and hydrochlorothiazide (HCT). The pill is already marketed as Amturnide in the US. The approval of Rasitrio was based on data [...]

11/28/11(MYL) Mylan Settles with Novartis (Stock Blog Hub)

Mylan, Inc. (MYL) recently announced a settlement agreement with Novartis (NVS) relating to the generic version of Novartis’ bioidentical estrogen therapy Vivelle-Dot. As a result of the resolution, the lawsuit filed by Novartis will be dismissed and Mylan can launch a generic version of Vivelle-Dot on December 16, 2013, or earlier under certain circumstances. Mylan was [...]

10/25/11What Does Novartis' Earnings Release Really Mean for the Company? (Benzinga)

Earlier this morning, Novartis (NYSE: NVS) reported poor earnings for their third quarter. The company matched analysts' EPS estimates of $1.45, but missed revenue estimates by reporting $14.8 billion instead of $15.1 billion. The firm also reported that it will be cutting 2,000 world-wide. Overall, Novartis is a global health care company that delves into the pharmaceutical space along with consumer health products. While it is apparent that the company did not perform as well as expected in...

9/20/11(NVS) Novartis Drug Cleared in EU for SEGA (Stock Blog Hub)

Novartis (NVS) recently received a boost when its drug Votubia was approved for the treatment of subependymal giant cell astrocytomas (SEGA), a benign brain tumor associated with tuberous sclerosis (TS) in the European Union (EU). For the first time ever will such a medication be available in this region for the treatment of this challenging disease. [...]

9/11/11(NVS) Novartis Neuroendocrine Tumors Drug Cleared in European Union (Stock Blog Hub)

Novartis’(NVS) drug Afinitor was recently approved in the European Union (EU) for the treatment of patients with advanced neuroendocrine tumors (NET) of pancreatic origin with progressive disease. The drug is already approved in the US for the indication. The approval was based on the RADIANT-3 trial which demonstrated that Afinitor led to a statistically significant improvement [...]

9/9/11Novartis AG (NVS) Dividend Stock Analysis (Dividend Growth Investor)

Novartis AG (NVS), through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Novartis is an international dividend achiever, has paid uninterrupted dividends on its common stock since 1992 and increased payments to common shareholders every year for 14 years. The most recent dividend increase was in November 2010, when the Board of Directors approved a 4.80% increase to 2.20 CHF/share. The largest competitors of Novartis...

9/1/11Novartis Stock Analysis (The DIV-Net)

Novartis AG (NVS), through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Novartis is an international dividend achiever, has paid uninterrupted dividends on its common stock since 1992 and increased payments to common shareholders every year for 14 years. The most recent dividend increase was in November 2010, when the Board of Directors approved a 4.80% increase to 2.20 CHF/share. The largest competitors of Novartis...

7/12/11(NVS) Novartis Presents Afinitor Data (Stock Blog Hub)

Recently, Novartis (NVS) presented data from a late-stage study (EXIST-1) of its cancer drug Afinitor (everolimus). The randomized, placebo-controlled, double-blind, multicenter study evaluated the safety and effectiveness of the drug compared to placebo for treating patients with subependymal giant cell astrocytomas (SEGAs) coupled with tuberous sclerosis (TS). Results from the study were presented at the [...]

7/11/11(NVS) Novartis AG’s Lung Drug Cleared in US (Stock Blog Hub)

Novartis AG (NVS) recently announced that its once-daily long-acting beta2-agonist (LABA) Arcapta Neohaler (75 mcg) was cleared by the US Food and Drug Administration (FDA) for the long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema. With the approval, Arcapta becomes the first therapy [...]

7/7/11(NVS) Novartis AG’s Afinitor Impresses Again (Stock Blog Hub)

It seems Novartis AG’s (NVS) breast cancer drug, Afinitor (everolimus), is getting into a habit of delivering positive news. Right after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Afinitor last week for the treatment of subependymal giant cell astrocytomas (SEGA), the drug impressed again [...]

7/7/11(SHPGY) Shire Entangled in Legal Dispute (Stock Blog Hub)

The legal tussle between Shire (SHPGY), Sandoz, Inc. -- the generic arm of Novartis (NVS) and Amneal Pharmaceuticals -- intensified with Shire filing a patent infringement case against the two companies relating to Vyvanse. Vyvanse is indicated for treating patients suffering from attention deficit hyperactive disorder (ADHD). Amneal and Sandoz have filed abbreviated new drug applications [...]

6/29/11(NVS) Novartis AG Afinitor Backed in EU (Stock Blog Hub)

Novartis AG (NVS) received a boost recently when the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of its drug Afinitor for the treatment of subependymal giant cell astrocytomas (SEGA), a benign brain tumor associated with tuberous sclerosis (TS), in the European Union. The European Commission is [...]

6/22/11(NVS) Novartis Gets Setback From FDA Panel (Stock Blog Hub)

Novartis (NVS) received a setback recently when an advisory panel to the US Food and Drug Administration (FDA) recommended against approving its pipeline candidate ACZ885 for the proposed indication. Novartis was seeking approval to expand the use of ACZ885 for the treatment of patients suffering from severe gouty arthritis, commonly known as gout, who failed to [...]

6/6/11Gen-Probe shares fall after report one bidder left (Penny Stock DD)

Gen-Probe Inc (GPRO.O) shares fell 13 percent after a published report said Swiss drugmaker Novartis AG (NOVN.VX) appeared to be the last company bidding to buy the medical diagnostics test maker, and suggested that a deal might not go through at all. While Novartis, which has a blood-testing partnership with Gen-Probe, has been [...]

6/6/11Market Weakness Will Create Buying Opportunity, But When? (EXEL, GPRO, NVS, HOG, ABC, CNIT) (tickerspy.com)

The market continued its losing ways, as stocks extended their losses late in the day. We've been saying that we were expecting the market to be weak this summer, and thus far that is playing out as the economic data has been lackluster. However, at this point we still think this is a small [...]

6/6/11Hormone-blocking drug reduces breast cancer risk (Penny Stock DD)

Millions of women at higher-than-usual risk of breast cancer have a new option for preventing the disease. Pfizer Inc.'s Aromasin cut the risk of developing breast cancer by more than half, without the side effects that have curbed enthusiasm for other prevention drugs, a major study found. It was the first test [...]

4/27/11(NVS) Novartis Posts Solid First Quarter Sales (Stock Blog Hub)

Novartis (NVS) reported earnings per share of $1.41 for the first quarter of 2011, below the year-earlier earnings of $1.45 per share but well ahead of the Zacks Consensus Estimate of $1.31. The drop from the base period resulted from financing costs for the Alcon acquisition completed in April this year. An increase in the [...]

4/13/11(NVS) Novartis’ Tasigna Trial for Gastrointestinal Stromal Tumor Halted (Stock Blog Hub)

Novartis (NVS) faced a pipeline setback recently as it announced discontinuation of a late-stage study (ENESTg1) of its drug Tasigna on the recommendation of an independent data monitoring committee. The study evaluated Tasigna versus Glivec as a first-line treatment for unresectableor metastatic GIST (gastrointestinal stromal tumor), a form of stomach cancer. Both Tasigna and Glivec are [...]

2/18/11Obama Hates Your Drugmaker (Penny Stock DD)

President Obama wants to see inexpensive generics hit the pharmacy shelves sooner. While that would be good for your pocketbook, it would wreak havoc on drugmakers that sell branded drugs. Obama's budget proposal includes a provision to reduce a 12-year exclusivity period that biologic drugs have down to just seven years. Allowing biosimilars from [...]

2/1/11Novartis: A Great Conservative Growth Stock (The Iconoclast Investor)

Still there are opportunities for investors in Switzerland. Which brings me to this issue’s recommendation. It’s pharmaceutical giant Novartis (NVS), which is headquartered in Basel, Switzerland, but does business in 140 countries all over the world. Created in 1996 from the merger of Ciba-Geigy and Sandoz, the company generated $51 billion in revenues last year. Its biggest [...]

12/17/10Alcon Agrees to Novartis Deal in Consensus Hedge Fund Arbitrage Trade (Penny Stock DD)

Alcon (ACL) has reached an agreement to sell the remaining 23% of the company to Swiss drug maker, Novartis (NVS). Novartis is offering 2.8 shares of NVS for each share of ACL, the equivalent of $168 for each ACL share. The deal is supposed to close [...]

12/16/10Alcon Agrees Novartis Deal in Consensus Hedge Fund Arbitrage Trade (market folly)

Alcon (ACL) has reached an agreement to sell the remaining 23% of the company to Swiss drug maker, Novartis (NVS). Novartis is offering 2.8 shares of NVS for each share of ACL, the equivalent of $168 for each ACL share. The deal is supposed to close in the first half of 2011, pending shareholder approval. While Novartis' offer comes in at $168 per share, ACL is currently trading just above $164. The deal is contingent upon shareholder approval and if you examine the list of shareholders,...

12/15/10Stock Rally Stalling (JOYG, SAM, BRCM, NVS, ACL) (tickerspy.com)

Stocks continued their recent trend of giving up gains late in the day, despite the Senate passing a bill to extend tax cuts. Debt worries over Europe and a stronger dollar were largely to blame. For now the stock rally seems to have stalled a bit, although we're still generally optimistic heading into year-end. [...]

11/3/10Positive Results In Study of Novartis Drug Afinitor (NVS) (Benzinga)

Novartis AG (NYSE: NVS) reported after the close today, November 3rd The New England Journal of Medicine published a study which found patients taking Afinitor tablets saw a decrease in the size of their subependymal giant cell astrocytoma. Astrocytoma's are a benign brain tumor associated with TB 1 and 2. The company stated during a presentation at the 46th annual American Society of Clinical Oncology annual meeting this is the first study to show a beneficial use of the drug in...

10/18/10Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® for $400 Million (Benzinga)

Warner Chilcott plc (Nasdaq: WCRX) today announced that it has completed its acquisition of the U.S. rights to Enablex® from Novartis for $400 million in cash. Enablex is a product indicated to treat adults with symptoms of overactive bladder, which had U.S. sales of approximately $190 million for the year ended December 31, 2009. Concurrently with the closing of the transaction, Warner Chilcott and Novartis terminated their existing co-promotion agreement, and Warner Chilcott assumed...

10/7/10Cepheid Collaborates With Novartis on Chronic Myelogenous Leukemia (Benzinga)

Cepheid today announced an exclusive collaboration with Novartis for the commercialization of a test for monitoring the BCR-ABL gene transcript in peripheral blood specimens from patients diagnosed with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML). Together with other lab tests, monitoring levels of BCR-ABL transcripts in Ph+ CML patients will aid in patient management. The collaboration reflects the commitment shared by Novartis and Cepheid to deliver the...

10/6/10S&P Downgrades Novartis AG (NVS) From Buy to Hold (Benzinga)

S&P Downgraded Novartis AG (NYSE: NVS) From Buy to Hold, yesterday. The price target was cut from 66 to 60 on the European traded shares. There was no equivalent price target given for the NY traded shares, as the report came from S&P Europe. Here are a few quotes from the report: “Novartis announced today it has stopped development of two late-stage pipeline assets - Mycograb (antifungal) and albinterferon alfa-2b (Hep C). The relating intangible asset impairment totaling US$590...

10/4/10Alcon Names New CFO (Benzinga)

Alcon, Inc. (NYSE: ACL) announced today the appointment of Robert Karsunky as senior vice president and chief financial officer effective November 1, 2010. Karsunky comes to Alcon from Novartis AG, where he was most recently chief financial officer in the Consumer Health Division of Novartis. Novartis became Alcon's majority shareholder on August 25, when it completed the acquisition of 52 percent of the company's shares from Nestle SA. Novartis now owns 77 percent of Alcon's outstanding...

10/2/10(NVS) Novartis AG Earns FDA Approval of Oral Multiple Sclerosis Drug (Stock Blog Hub)

Novartis AG (NVS) received a huge boost recently with the US Food and Drug Administration (FDA) approving its oral multiple sclerosis (MS) drug, Gilenya. Gilenya is the first oral treatment to gain US approval for the first-line treatment of relapsing forms of MS. The drug is shown to significantly reduce relapse rates and delay disability [...]

9/22/10Biogen Falling On Novartis Approval (Benzinga)

Shares of Biogen Idec Inc. (NASDAQ: BIIB) are getting hit hard today after Swiss drug maker Novartis AG (NYSE: NVS) said it received U.S. regulatory approval for the multiple-sclerosis drug Gilenya. The new drug is a pill, as opposed to injection, making it easier to administer to patients. Biogen's Avonex drug is an injection, and thus the new MS drug could potentially eat away at market share of Avonex. Shares of BIIB are down over 5% to $55.01, a loss of $3.22, while NVS was losing 23...

9/22/10Top 4 Large-Cap Stocks In The Drug Manufacturers–Major Industry With The Highest EPS Estimates ... (Benzinga)

Below are the top large-cap drug manufacturers–major stocks on the NYSE and the NASDAQ in terms of earnings estimate for the next year. The earnings estimate for AstraZeneca Plc (NYSE: AZN) for the next year ending December, 2011 is $6.49 per share. AZN's trailing-twelve-month ROE is 42.88%. Novartis AG (NYSE: NVS) is expected to earn $5.03 per share over the next year ending December, 2011. NVS' trailing-twelve-month operating margin is 24.62%. Abbott Laboratories (NYSE: ABT) is...


Your blog posts can appear here by joining the Wikinvest Wire
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki